You can collect some of the best yields in the market right now from packaging, pipelines, and power.

The catch is that each of these payers reports within the next five weeks, and those reports will tell you whether the income is funded or living on borrowed time.

What Elon is doing in AI is exactly what he’s done his entire career.  

He took over mobile payments with PayPal.

Electric cars with Tesla.

Commercial space launches with SpaceX.  

Now he’s doing it with Artificial Intelligence… and James Altucher believes we could see as many as 1.8 MILLION new “Musk millionaires” over the next decade from his impending AI takeover.  

According to James Altucher, there’s one company sitting at the dead center of his plan… and it's still trading for less than $100.  

James compiled all the critical details you need to position yourself early in this FREE Millionaire Maker Masterclass.

VIEW IT NOW

NIKE, Inc. (NYSE: NKE) is pushing its turnaround into a deeper phase with more job cuts and a restructuring of the business around three geographic regions. Management is also targeting persistent weakness in Greater China, Jordan Brand, and Nike Sportswear as the recovery takes longer than originally expected.

The changes go beyond reducing costs. Nike is trying to rebuild retailer relationships, put performance sports back at the center of the brand, improve product innovation, and regain control over discounting.

China Remains One of the Biggest Tests

Greater China has been one of Nike’s toughest markets, with local competition rising and demand for some older lifestyle products weakening. Management is responding by changing distribution and trying to restore excitement around the brand.

China therefore remains central to your assessment of whether Nike is fixing the business rather than simply cutting expenses.

Product Has to Carry the Recovery

Cost reductions can support margins, but they cannot replace products consumers actually want. Nike still needs stronger innovation across running, basketball, sportswear, and other major categories to create durable growth.

As the restructuring takes hold, you will have a clearer measure of progress: whether fresh products and stronger retail relationships can bring demand back without constant promotions.

NKE currently trades at $33 and pays a dividend of $1.64 per share, a yield of 4.95%.

Dell Technologies Inc. (NYSE: DELL) is joining Japanese power company JERA and infrastructure developer RHAELM on a planned $15 billion AI data-center project near Tokyo. Dell will provide the computing infrastructure, while JERA contributes the site and long-term power.

The first facility will be built in Chiba, but the partnership is designed to be repeated at additional locations across Japan. That allows Dell to turn one major deployment into a broader infrastructure relationship.

Dell Is Moving Beyond Its PC Identity

Dell still sells millions of computers, but its infrastructure business has become increasingly important as companies spend more on servers, storage, and systems built to handle AI workloads.

Keep thinking of Dell mainly as a PC company, and you miss where a 

growing part of the opportunity now sits. Data centers give the company exposure to much larger technology projects than a traditional device sale.

One Project Could Become a Larger Platform

The partners want to repeat the same model across Japan, particularly in locations where JERA already has access to energy infrastructure. Dell would then have a ready path into future projects without building a new commercial relationship each time.

If the model expands beyond Chiba, you move from a single equipment contract to a series of deployments tied to the same long-term AI infrastructure platform.

DELL currently trades at $526 and pays a dividend of $2.52 per share, a yield of 0.48%.

Bank of America just warned that a central bank digital dollar is "inevitable," setting the stage for total government oversight of your personal spending.

But a former Wall Street insider just revealed a quiet strategy over 4,500 investors are using to protect their wealth and generate yield outside the Fed's control.

Click here to see how to access this financial escape hatch before the window closes.

*This content is for educational purposes only. The opinions expressed are from DM Intelligence LLC, doing business as Decentralized Masters, who are not licensed financial advisors or registered investment advisors. The reader acknowledges that DM Intelligence LLC is not responsible for any losses, direct or indirect, resulting from the use of this information, including errors, omissions, or inaccuracies.

Results are not typical and will vary. Success with digital currencies requires time, effort, and involves substantial risk including total loss of investment. Past performance does not indicate future results. All investments are at your own risk.

Please click here if you would like to unsubscribe.

Sanofi (NASDAQ: SNY) has expanded its long-running partnership with Regeneron to develop four new immune-system treatments, paying $1 billion upfront with as much as $7 billion more tied to future progress. The companies will share development costs and potential profits from the new medicines.

The decision builds on the same partnership that produced Dupixent, now one of Sanofi’s most important products. Instead of starting from scratch with a new partner, Sanofi is going back to a relationship that has already produced a major commercial success.

A Proven Partnership Lowers Some of the Risk

Sanofi and Regeneron have worked together for more than two decades, combining Regeneron’s drug research with Sanofi’s global commercial reach. Their expanded agreement follows a model both companies already know well.

Focus only on the upfront payment, and you miss the larger advantage: Sanofi is building its next pipeline with a partner that already understands how to move medicines from research into a global market.

The Real Payoff Comes Years From Now

The four new programs still need to move through development, so their commercial impact will not arrive immediately. Sanofi is using current financial strength to create more growth options for the next decade.

By the time Dupixent faces heavier competition, you will care far more about whether these programs have become meaningful products than what Sanofi paid to start the partnership today.

SNY currently trades at $41 and pays a dividend of $1.76 per share, a yield of 4.29%.

American Financial Group (AFG) raised its quarterly dividend 10.2% to $0.97 per share from $0.88, a yield of about 2.8%.

T-Mobile US (TMUS) raised its quarterly dividend 15% to $1.17 per share from $1.02, a yield of about 2.9%.

Bank OZK (OZK) raised its quarterly dividend 2.1% to $0.49 per share from $0.48, its 65th straight quarterly increase, a yield of about 4.2%.

Conagra Brands (CAG) is holding its quarterly dividend at $0.175 per share after cutting it 50% from $0.35 this summer, a yield of about 5.2%.

Campbell's (CPB) now pays $0.25 per share each quarter after cutting its dividend 36% from $0.39 to pay down debt, a yield of about 5.1%.

The national debt has moved beyond $40 trillion, while rising interest costs are putting even more pressure on Washington’s finances.

Elon Musk says the long-term trajectory is unsustainable without dramatic economic growth.

For retirement savers, the bigger question is how much of their wealth remains exposed if markets get rough.

See the Retirement Strategy Built for the Next Financial Shock